title: Towards the next generation of biomedicines by site-selective conjugation.
abstract: Bioconjugates represent an emerging class of medicines, which offer therapeutic opportunities overtaking those of the individual components. Many novel bioconjugates have been explored in order to address various emerging medical needs. The last decade has witnessed the exponential growth of new site-selective bioconjugation techniques, however very few methods have made the way into human clinical trials. Here we discuss various applications of site-selective conjugation in biomedicines, including half-life extension, antibody-drug conjugates, conjugate vaccines, bispecific antibodies and cell therapy. The review is intended to highlight both the progress and challenges, and identify a potential roadmap to address the gap.
authors.affiliation: Novartis Institutes for Biomedical Research (NIBR), 100 Technology Square, Cambridge, MA 02139, USA. qiying.hu@novartis.com.
authors.forename: Qi-Ying
authors.initials: QY
authors.lastname: Hu
authors.affiliation: GSK Vaccines (former Novartis Vaccines & Diagnostics), Via Fiorentina 1, 53100 Siena, Italy. roberto.x.adamo@gsk.com.
authors.forename: Francesco
authors.initials: F
authors.lastname: Berti
authors.affiliation: GSK Vaccines (former Novartis Vaccines & Diagnostics), Via Fiorentina 1, 53100 Siena, Italy. roberto.x.adamo@gsk.com.
authors.forename: Roberto
authors.initials: R
authors.lastname: Adamo
mesh_terms: D016503:Drug Delivery Systems; D006801:Humans; D018796:Immunoconjugates
chemical_list: D018796:Immunoconjugates